Non sedating H1-antihistamine

Phase 3Small molecule

Non sedating H1-antihistamine is one of 44 small molecule programs targeting Cold Urticaria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cold UrticariaActive, not recruiting

Chronic Spontaneous UrticariaActive, not recruiting

Cold UrticariaPhase 3

Active, not recruiting

Chronic Spontaneous UrticariaPhase 3

Active, not recruiting

Competition

Competitive Landscape

59 competitors in Chronic Spontaneous Urticaria

#DrugCompanyPhaseTrials

Claritin

PPerrigo Company

Approved

1 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

4 3

Xolair

Roche

Phase 2

10 4

Bilaxten

MMenarini International Operations Luxembourg SA

Phase 3

1 5

LOU064

Novartis

Phase 3

2 6

Xolair

Roche

Phase 3

1 7

Opzelura

Pfizer

Phase 2

2 8

Barzolvolimab

CCelldex Therapeutics

Phase 3

4 9

Tezspire

AstraZeneca

Phase 2

1 10

Fasenra

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cold Urticaria1 trial

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

Completed· Sanofi logo

Sanofi·Phase 3·NCT04681729·82 enrolled

Chronic Spontaneous Urticaria1 trial

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Completed· Sanofi logo

Sanofi·Phase 3·NCT04180488·397 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Non sedating H1-antihistamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Non sedating H1-antihistamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Non sedating H1-antihistamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Non sedating H1-antihistamine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cold Urticaria1 trial

Chronic Spontaneous Urticaria1 trial

References

Drug Info

Quick Facts

Related News